Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of
Lung Cancer.
10.3779/j.issn.1009-3419.2023.102.45
- Author:
Yu ZHANG
1
;
Yanhong WANG
1
;
Mei LIU
2
Author Information
1. Department of Pathology, The Second People's Hospital of Baiyin City, Baiyin 730900, China.
2. Health Company of PLA 68303 Troops, Baiyin 730900, China.
- Publication Type:Journal Article
- Keywords:
Long non-coding RNA THAP7-AS1;
Lung neoplasms;
Methyltransferase-like 3;
N6-methyladenosine;
Proliferation
- MeSH:
Humans;
Lung Neoplasms/pathology*;
RNA, Long Noncoding/metabolism*;
Phosphatidylinositol 3-Kinases/metabolism*;
Up-Regulation;
Proto-Oncogene Proteins c-akt/metabolism*;
Cell Line, Tumor;
Cell Proliferation/genetics*;
Gene Expression Regulation, Neoplastic;
Methyltransferases/metabolism*;
Cullin Proteins/genetics*
- From:
Chinese Journal of Lung Cancer
2024;26(12):919-933
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Lung cancer is a major threat to human health. The molecular mechanisms related to the occurrence and development of lung cancer are complex and poorly known. Exploring molecular markers related to the development of lung cancer is helpful to improve the effect of early diagnosis and treatment. Long non-coding RNA (lncRNA) THAP7-AS1 is known to be highly expressed in gastric cancer, but has been less studied in other cancers. The aim of the study is to explore the role and mechanism of methyltransferase-like 3 (METTL3) mediated up-regulation of N6-methyladenosine (m6A) modified lncRNA THAP7-AS1 expression in promoting the development of lung cancer.
METHODS:Samples of 120 lung cancer and corresponding paracancerous tissues were collected. LncRNA microarrays were used to analyze differentially expressed lncRNAs. THAP7-AS1 levels were detected in lung cancer, adjacent normal tissues and lung cancer cell lines by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The diagnostic value of THAP7-AS1 in lung cancer and the relationship between THAP7-AS1 expression and survival rate and clinicopathological parameters were analyzed. Bioinformatics analysis, methylated RNA immunoprecipitation (meRIP), RNA pull-down and RNA-immunoprecipitation (RIP) assay were used to investigate the molecular regulation mechanism of THAP7-AS1. Cell proliferation, migration, invasion and tumorigenesis of SPC-A-1 and NCI-H1299 cells were determined by MTS, colony-formation, scratch, Transwell and xenotransplantation in vivo, respectively. Expression levels of phosphoinositide 3-kinase/protein kenase B (PI3K/AKT) signal pathway related protein were detected by Western blot.
RESULTS:Expression levels of THAP7-AS1 were higher in lung cancer tissues and cell lines (P<0.05). THAP7-AS1 has certain diagnostic value in lung cancer [area under the curve (AUC)=0.737], and its expression associated with overall survival rate, tumor size, tumor-node-metastasis (TNM) stage and lymph node metastasis (P<0.05). METTL3-mediated m6A modification enhanced THAP7-AS1 expression. The cell proliferation, migration, invasion and the volume and mass of transplanted tumor were all higher in the THAP7-AS1 group compared with the NC group and sh-NC group of SPC-A-1 and NCI-H1299 cells, while the cell proliferation, migration and invasion were lower in the sh-THAP7-AS1 group (P<0.05). THAP7-AS1 binds specifically to Cullin 4B (CUL4B). The cell proliferation, migration, invasion, and expression levels of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphoinositide-3 kinase, catalytic subunit delta (PIK3CD), phospho-phosphatidylinositol 3-kinase (p-PI3K), phospho-protein kinase B (p-AKT) and phospho-mammalian target of rapamycin (p-mTOR) were higher in the THAP7-AS1 group compared with the Vector group of SPC-A-1 and NCI-H1299 cells (P<0.05).
CONCLUSIONS:LncRNA THAP7-AS1 is stably expressed through m6A modification mediated by METTL3, and combines with CUL4B to activate PI3K/AKT signal pathway, which promotes the occurrence and development of lung cancer.